Immunophenotyping of the patient at different years of age
| . | Patient . | Ref. . | Patient . | Ref. . | Patient . | Ref. . | ||
|---|---|---|---|---|---|---|---|---|
| Age at evaluation (years) | 4 | 6 | 3–6 | 10 | 7–12 | 14 | 17 | 13–18 |
| T lymphocytes | | | | | | | | |
| CD3+ (/μl) | 1,304 | 1,043 | 1,400–3,700 | 1,260 | 1,200–2,600 | 916 | 672 | 1,000–2,200 |
| CD3+CD4+ (/μl) | 775 | 575 | 700–2,200 | 780 | 650–1,500 | 476 | 365 | 530–1,300 |
| Naive CD4+ CD45RA+ % | NA | 24.5 | 53–86 | NA | 46–77 | 39 | 40 | 33–66 |
| Memory CD4+ CD45RO+ % | NA | 24.5 | 9–26 | NA | 13–30 | 29.5 | 35 | 18–38 |
| T reg CD4+ CD25+CD127LOW % | NA | 4.6 | 4.2–12.5 | NA | 4.2–12.5 | NA | NA | 4.2–10.5 |
| CD8+ (/μl) | 454 | 378 | 490–1,300 | 490 | 370–1,100 | 297 | 221 | 330–920 |
| Naive CD8+ CCR7+CD45RA+ % | NA | 69.7 | 52–68 | NA | 40–75 | 51 | 48 | 52–68 |
| Central memory CD8+ CCR7+CD45RA− % | NA | 1 | 12–30 | NA | 13–37 | 4 | 5 | 10–31 |
| Effector memory CD8+CCR7−CD45RA− % | NA | 10.6 | 1.5–13 | NA | 1.5–15 | 29 | 28 | 2.3–15 |
| Terminal effector CD8+CCR7−CD45RA+ % | NA | 39.6 | 1.7–24 | NA | 2–21 | 16 | 19 | 5–31 |
| Natural killer cells | | | | | | | | |
| CD3−CD56+ (/μl) | 114 | 91 | 130–720 | 120 | 100–480 | NA | NA | 70–480 |
| B lymphocytes | | | | | | | | |
| CD19+ (/μl) | 397 | 161 | 273–860 | 350 | 219–509 | 226 | 163 | 193–628 |
| Naive B cells CD27−IgD+ % | NA | 75 | 59.7–88.4 | NA | 58.5–84.6 | 89 | 79 | 61.6–87.4 |
| Memory B cells CD27+ % | NA | NA | 8.1–33.3 | NA | 9–35 | 7 | 18 | 14.6–26.6 |
| Unswitched memory CD27+IgD+ % | NA | 12 | 3.1–18 | NA | 3–21.1 | 4.4 | 12 | 2.6–13.4 |
| Switched memory CD27+IgD− % | NA | 10 | 2.9–17.4 | NA | 4.4–20.5 | 3 | 6 | 4–21.2 |
| Transitional CD24++CD38++ % | NA | 12 | 5.4–9.2 | NA | 4.5–9.2 | 3 | 7 | 3.9–7.8 |
| Plasmablast CD24−CD38++ % | NA | 0 | 0.8–2.7 | NA | 0.7–3.5 | 0.6 | 0.4 | 0.3–1.7 |
| CD19+ CD21−CD38− % | NA | 2 | 1.8–5.2 | NA | 0.9–3.5 | 2 | 3 | 0.9–3.3 |
| . | Patient . | Ref. . | Patient . | Ref. . | Patient . | Ref. . | ||
|---|---|---|---|---|---|---|---|---|
| Age at evaluation (years) | 4 | 6 | 3–6 | 10 | 7–12 | 14 | 17 | 13–18 |
| T lymphocytes | | | | | | | | |
| CD3+ (/μl) | 1,304 | 1,043 | 1,400–3,700 | 1,260 | 1,200–2,600 | 916 | 672 | 1,000–2,200 |
| CD3+CD4+ (/μl) | 775 | 575 | 700–2,200 | 780 | 650–1,500 | 476 | 365 | 530–1,300 |
| Naive CD4+ CD45RA+ % | NA | 24.5 | 53–86 | NA | 46–77 | 39 | 40 | 33–66 |
| Memory CD4+ CD45RO+ % | NA | 24.5 | 9–26 | NA | 13–30 | 29.5 | 35 | 18–38 |
| T reg CD4+ CD25+CD127LOW % | NA | 4.6 | 4.2–12.5 | NA | 4.2–12.5 | NA | NA | 4.2–10.5 |
| CD8+ (/μl) | 454 | 378 | 490–1,300 | 490 | 370–1,100 | 297 | 221 | 330–920 |
| Naive CD8+ CCR7+CD45RA+ % | NA | 69.7 | 52–68 | NA | 40–75 | 51 | 48 | 52–68 |
| Central memory CD8+ CCR7+CD45RA− % | NA | 1 | 12–30 | NA | 13–37 | 4 | 5 | 10–31 |
| Effector memory CD8+CCR7−CD45RA− % | NA | 10.6 | 1.5–13 | NA | 1.5–15 | 29 | 28 | 2.3–15 |
| Terminal effector CD8+CCR7−CD45RA+ % | NA | 39.6 | 1.7–24 | NA | 2–21 | 16 | 19 | 5–31 |
| Natural killer cells | | | | | | | | |
| CD3−CD56+ (/μl) | 114 | 91 | 130–720 | 120 | 100–480 | NA | NA | 70–480 |
| B lymphocytes | | | | | | | | |
| CD19+ (/μl) | 397 | 161 | 273–860 | 350 | 219–509 | 226 | 163 | 193–628 |
| Naive B cells CD27−IgD+ % | NA | 75 | 59.7–88.4 | NA | 58.5–84.6 | 89 | 79 | 61.6–87.4 |
| Memory B cells CD27+ % | NA | NA | 8.1–33.3 | NA | 9–35 | 7 | 18 | 14.6–26.6 |
| Unswitched memory CD27+IgD+ % | NA | 12 | 3.1–18 | NA | 3–21.1 | 4.4 | 12 | 2.6–13.4 |
| Switched memory CD27+IgD− % | NA | 10 | 2.9–17.4 | NA | 4.4–20.5 | 3 | 6 | 4–21.2 |
| Transitional CD24++CD38++ % | NA | 12 | 5.4–9.2 | NA | 4.5–9.2 | 3 | 7 | 3.9–7.8 |
| Plasmablast CD24−CD38++ % | NA | 0 | 0.8–2.7 | NA | 0.7–3.5 | 0.6 | 0.4 | 0.3–1.7 |
| CD19+ CD21−CD38− % | NA | 2 | 1.8–5.2 | NA | 0.9–3.5 | 2 | 3 | 0.9–3.3 |
Summary of immunophenotyping results from the hospital laboratory. NA, not available. Values above or below reference (Ref.) ranges are marked in bold.